Journal of Clinical Oncology
Articles in this Issue
Navigator-assisted hypofractionation (NAVAH) phase I clinical trial of breast cancer patients: Implications for assessing personal versus familial financial toxicity via the Comprehensive Score for Financial Toxicity-Functional Assessment of Chronic Illness Therapy (COST-FACIT) survey instrument.
e23180 Background: The COST-FACIT survey has been used to objectively measure financial toxicity (FT). It consists of 11 questions related to FT of an ind...
Cross-state variations and temporal trends in tracheal, bronchus and lung cancer burden in India from 1990-2021: Mortality projections to 2050.
e22520 Background: Tracheal, Bronchus and Lung Cancer (TBLc) is the 2nd leading cause of death and 3rd leading cause of disability in India, with rising i...
Meeting enrollment targets in IMbrave152/SKYSCRAPER-14, a global phase 3 study in patients with unresectable hepatocellular carcinoma (HCC).
1585 Background: The FDA has released guidance that the patient population in clinical studies should be representative of the intended-use population and...
Prognostic impact of homologous recombination deficiency in advanced breast cancer treated with trastuzumab deruxtecan.
e13046 Background: Trastuzumab deruxtecan (T-DXd) has redefined the treatment paradigm of HER2-positive or HER2-low advanced breast cancer (ABC). While ho...
Exploring steroid prophylaxis to mitigate CRS: Enhancing access to bispecific antibodies in RRMM.
e19537 Background: Talquetamab, an FDA-approved bispecific antibody (bsAb) for relapsed/refractory multiple myeloma (RRMM), demonstrates an ORR >70% an...
Comparison of ctDNA and hematologic ratios as markers of disease progression in early versus late-stage melanoma: A single-center retrospective study.
e21539 Background: Hematologic ratios , such as the Neutrophil – Lymphocyte Ratio (NLR) , Monocyte – Lymphocyte Ratio (MLR) , and Platelet – Lymphocyte Ra...
Does the surgeon's learning curve impact pentafecta outcomes in radical prostatectomy? A systematic review and meta-analysis.
e17143 Background: Radical prostatectomy is a key treatment for prostate cancer. However, the impact of the learning curve of the surgeon has on the penta...
Gauging sustainable cancer (CA) prevention in Lynch syndrome (LS): Attitudes toward dietary interventions.
e15655 Background: LS is among the most common hereditary CA syndromes, characterized by autosomal dominant inheritance of mismatch repair deficiency with...
Real-world efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific antibody) in patients with advanced, recurrent, and metastatic cervical cancer.
5537 Background: Immune checkpoint inhibitors have become one of the important treatment modalities for advanced, recurrent and metastatic cervical cancer...
Use of lucicebtide (ST101) in glioblastoma patients by antagonism of C/EBPβ-dependent mesenchymal cell transition and immunosuppressive M2 macrophage polarization.
2016 Background: C/EBPβ is a master regulator of the mesenchymal phenotype in GBM and has an essential role in the mainten...
Health economic impact of active e-health support in patients with advanced and metastatic breast cancer.
e13726 Background: The AGO-B/WSG PreCycle trial demonstrated that patients with advanced/metastatic HR+/HER2- breast cancer receiving palbociclib and endo...
Detecting ctDNA using personalized structural variants to forecast recurrence in localized soft tissue sarcoma (STS).
11511 Background: The current standard for definitive management of localized STS involves surgery and (neo)adjuvant radiation (RT). Unfortunately, up to...
Proton pump inhibitors and clinical outcomes in hepatocellular carcinoma patients: A propensity score–matched analysis from a global federated dataset.
e16270 Background: Proton pump inhibitors (PPIs) are commonly prescribed in patients with hepatocellular carcinoma (HCC) to manage gastroesophageal reflux...
Risk of autoimmune hepatitis, non-infectious gastroenteritis, and colitis among patients with metastatic clear cell renal cell carcinoma (ccRCC) treated with pembrolizumab/axitinib vs nivolumab/ipilimumab.
e16530 Background: The treatment landscape for RCC has advanced with targeted therapies and ICIs enabling personalized approaches based on patient charact...
I-SPY2 endocrine optimization pilot (EOP): Neoadjuvant lasofoxifene (Laso) in molecularly selected patients with hormone receptor positive (HR+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC).
612 Background: EOP, an I-SPY2 sub-study, evaluates the tolerability and activity of novel endocrine strategies in stage 2/3 breast cancer (BC) patients (...
Treatment and outcomes of breast cancer with leptomeningeal disease: Real-world experience in the African American population.
e13106 Background: Leptomeningeal disease (LMD) is a rare but devastating complication of malignancies, affecting up to 5% of breast cancer patients. Surv...
Survival analysis and prognostication of cholangiocarcinoma: A SEER database study.
e16208 Background: Cholangiocarcinoma, a rare but highly lethal malignancy arising from the bile duct epithelium, presents a significant clinical challeng...
SCRUM-Japan MONSTAR-SCREEN-3: Comprehensive tumor microenvironment analysis via multi-omics in a large-scale prospective study.
TPS3170 Background: SCRUM-Japan is a multi-institutional, industry-academia collaborative cancer genome screening project launched in 2015, consisting of...
Clinical and biological subtypes of follicular lymphoma revealed by tumor and immune cell states.
7070 Background: Follicular lymphoma (FL) exhibits considerable variability in biological features and clinical trajectories, compounded by a complex tumo...
Burden of induced vasomotor symptoms in patients with HR+ breast cancer receiving adjuvant endocrine therapy.
e12504 Background: Adjuvant endocrine therapy (AET) is standard treatment for hormone-receptor positive (HR+) breast cancer (BC) and is associated with in...
Comparative efficacy and safety of nivolumab vs. docetaxel as second-line treatment in advanced non-small cell lung cancer: A systematic review and meta-analysis.
e20008 Background: In patients with stage IIIB-IV non-small cell lung cancer (NSCLC), response to first-line therapy is typically short-lived. Docetaxel i...
Effectiveness and safety of the amivantamab to lazertinib versus lazertinib alone in EGFR mutant metastatic non-small-cell lung cancer: Systematic review and meta-analysis.
e20677 Background: Epidermal Growth Factor Receptor (EGFR) mutant metastatic non-small-cell lung cancer (NSCLC) is a major global health problem. Targeted...
Randomized phase II trial evaluating the combination of TG4001, an HPV16 therapeutic vaccine, and avelumab (ave) in patients (pts) with immunotherapy-naïve recurrent and/or metastatic (R/M) HPV16-positive cervical or anogenital cancer.
2638 Background: Human papillomavirus (HPV) is a small DNA virus associated with cervical, anogenital (AG) cancers and squamous cell carcinoma of the head...
Machine learning for cancer risk stratification: A bi-directional approach to screening.
10526 Background: Cancer screening programs are often limited by high costs, invasiveness, and potential false results. Machine learning (ML) applied to r...
A phase 2 study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab in advanced leiomyosarcoma and liposarcoma (NCT04535713).
11515 Background: Chemotherapy agents cemcitabine, doxorubicin, and docetaxel have all demonstrated efficacy in soft tissue sarcomas (STS) but often resul...